BACKGROUND: Patients with diffuse cutaneous systemic sclerosis (dcSSc) have a poor prognosis. The importance of monitoring subjective measures of functioning and disability, such as the Health Assessment Questionnaire-Disability Index (HAQ-DI), is important as dcSSc is rated by patients as worse than diabetes or hemodialysis for quality of life impairment. This European Scleroderma Trials and Research (EUSTAR) database analysis was undertaken to examine the importance of impaired functionality in dcSSc prognosis. The primary objectives were to identify predictors of death and HAQ-DI score progression over 1 year. HAQ-DI score, major advanced organ involvement, and death rate were also used to develop a comprehensive model to predict lifetim...
Objectives: The multisystem manifestations of SSc can greatly impact patients' quality of life. The ...
Objectives. Our aim was to describe the burden of early dcSSc in terms of disability, fatigue and pa...
Objectives. Our aim was to describe the burden of early dcSSc in terms of disability, fatigue and pa...
BACKGROUND: Patients with diffuse cutaneous systemic sclerosis (dcSSc) have a poor prognosis. The im...
OBJECTIVES: Mortality and worsening of organ function are desirable endpoints for clinical trials in...
Objective: The burden of disability associated with systemic sclerosis (SSc) is being increasingly r...
Objectives Mortality and worsening of organ function are desirable endpoints for clinical trials in ...
Objectives: Our aim was to describe the burden of early dcSSc in terms of disability, fatigue and pa...
OBJECTIVES: To compare the ability of the Disease Activity Score (DAS) and the Revised EUSTAR Activi...
Objectives: Mortality and worsening of organ function are desirable endpoints for clinical trials in...
Objectives: Our aim was to describe the burden of early dcSSc in terms of disability, fatigue and pa...
Objectives Mortality and worsening of organ function are desirable endpoints for clinical trials in ...
OBJECTIVES: Mortality and worsening of organ function are desirable endpoints for clinical trials in...
Objectives: The multisystem manifestations of SSc can greatly impact patients' quality of life. The ...
Objectives. Our aim was to describe the burden of early dcSSc in terms of disability, fatigue and pa...
Objectives. Our aim was to describe the burden of early dcSSc in terms of disability, fatigue and pa...
BACKGROUND: Patients with diffuse cutaneous systemic sclerosis (dcSSc) have a poor prognosis. The im...
OBJECTIVES: Mortality and worsening of organ function are desirable endpoints for clinical trials in...
Objective: The burden of disability associated with systemic sclerosis (SSc) is being increasingly r...
Objectives Mortality and worsening of organ function are desirable endpoints for clinical trials in ...
Objectives: Our aim was to describe the burden of early dcSSc in terms of disability, fatigue and pa...
OBJECTIVES: To compare the ability of the Disease Activity Score (DAS) and the Revised EUSTAR Activi...
Objectives: Mortality and worsening of organ function are desirable endpoints for clinical trials in...
Objectives: Our aim was to describe the burden of early dcSSc in terms of disability, fatigue and pa...
Objectives Mortality and worsening of organ function are desirable endpoints for clinical trials in ...
OBJECTIVES: Mortality and worsening of organ function are desirable endpoints for clinical trials in...
Objectives: The multisystem manifestations of SSc can greatly impact patients' quality of life. The ...
Objectives. Our aim was to describe the burden of early dcSSc in terms of disability, fatigue and pa...
Objectives. Our aim was to describe the burden of early dcSSc in terms of disability, fatigue and pa...